Fourth quarter 2025 revenue increased by 15.9% to $539.1 million, with net income rising 58.7% to $36.2 million. Full-year 2025 revenue grew 13.9% to $2,163.4 million, and Adjusted EBITDA increased 14.6% to $431.9 million. Patient visits per day increased by 9.0% in Q4 2025 and 7.7% for the full year 2025, demonstrating strong volume growth. Revenue per visit rose 3.1% in Q4 2025 to $149.63 and 4.3% for the full year 2025 to $147.42. The company expanded its footprint, ending 2025 with 628 occupational health centers (up from 552 in Q4 2024) and 411 onsite health clinics (up from 157 in Q4 2024). A cash dividend of $0.0625 per share was declared, payable on or about March 19, 2026, to stockholders of record as of March 12, 2026. Approximately 1.1 million shares of common stock were repurchased in Q4 2025, totaling $22.4 million, as part of a $100 million share repurchase program. Net leverage ratio improved to 3.4x as of December 31, 2025, beating previously issued guidance of 3.5x, with a target of 3.0x or below by the end of 2026. Free Cash Flow for the full year 2025 was $197.8 million, with Q4 2025 Free Cash Flow at $98.6 million.